Search

M2 PRESSWIRE-June 19, 2024-: Cytomegalovirus Infection Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Chimerix, VBI Vaccines, Atara Biotherapeutics, Merck Sharp & Dohme [...]

- Funds to support the advancement of SF001, a next-generation polyene antifungal designed for reduced toxicity NEW YORK, June 17, 2024 /PRNewswire/ --https://c212.net/c/link/?t=0&l=en&o=4191829-1&h=3756122621&u=https%3A%2F%2Fwww.sfunga.com%2F&a=Elion+Therapeutics('Elion', formerly Sfunga Therapeutics), a biotechnology company dedicated [...]

2024 JUL 28 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Investigators discuss new findings in West Nile fever. According to [...]

2024 JUN 25 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on bacterial infections and mycoses. According to news originating from Kaifeng, [...]

2024 JUN 2 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Current study results on COVID-19 have been published. According to [...]

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ('BiomX' or the 'Company'), a clinical-stage company advancing novel natural and engineered phage [...]

New data from the largest European real-world evidence study of cefiderocol demonstrate positive outcomes including high rates of clinical success and day 28 survival across Gram-negative pathogens considered as critical [...]

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients [...]

- Efficacy and Safety Profile of Once-Daily Vemlidy Demonstrated in Children Six Years of Age (Weighing at Least 25kg) and Older - FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq: [...]

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a private clinical-stage biopharmaceutical company focused on viral and liver diseases, today announced the European Medicines Agency (EMA) [...]

Data published in Advanced Science and Bioengineering and Translational Medicine evaluates the efficacy of intranasal delivery of antibodies to RSV-infected neonatal lambs and SARS-CoV-2 infected hamsters DURHAM, N.C. -- Inhalon [...]

STIMULAN, when mixed with antibiotics, can be used for the treatment of bacterial infection STIMULAN will be distributed exclusively by Bone Surgical in Brazil KEELE, England, March 13, 2024 /PRNewswire/ [...]

Second orphan drug designation granted for pravibismane, in addition to the treatment of pulmonary infections in patients with cystic fibrosis Pravibismane demonstrated statistically significant in vivo efficacy against NTM in [...]

COPENHAGEN, Denmark, Jan. 9, 2024 /PRNewswire/ -- The Novo Nordisk Foundation is committing up to USD 25 million to support the early-stage development of innovative tools to prevent, diagnose and [...]

ZELSUVMI[TM] is expected to be commercially available during the second half of 2024 SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration [...]

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ('BiomX'), a clinical-stage company advancing novel natural and engineered phage therapies that target [...]

ZILBRYSQ(zilucoplan) is now commercially available by prescription in the United States and dispensed by UCB's selected exclusive specialty pharmacy PANTHERx Rare Pharmacy. ZILBRYSQ is FDA-approved as the first and only [...]

DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for VT-X7, Osteal Therapeutics' ('Osteal's') investigational drug therapy for periprosthetic joint infection [...]

- First and only FDA-approved antimicrobial catheter lock solution in the U.S. - Company expects DefenCath to be available in Q1 2024 in the inpatient setting BERKELEY HEIGHTS, N.J., Nov. [...]

Wilmington, Delaware, United States, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global anti-infective drugs market is projected to flourish https://www.globenewswire.com/Tracker?data=oQaTmMtzQxeTUf_GzLBSquE0I79TNC4IzRxJk32eb1NmLN_OKWmitzvFW-VPnXAJ5zZcXH8_D7_UMiDYqBzyCB78wWGCfXorLl7IyLZMpzSPkbYYRPPlZSrY3zeNxI4jUUt9ewZ4Cir-Jd3t2785YR43tEoUMe94YDcR0GSkaGI= from 2023 to 2031. As [...]

Pune, India, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Malaria is a serious infection spread by an infected mosquito. The infection is very common in certain parts of the world, such [...]

Planning for a December 2023 U.S. launch for H. pylori , together with the U.S. launch of vonoprazan for Erosive GERD, if approved FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE [...]

The global macrolide antibiotics market is expanding rapidly due to factors such as a rise in incidences of bacterial infections, availability of generic medications and significant demand for macrolides from [...]

LONDON, Oct. 12, 2023 /PRNewswire/ -- https://www.diseaselandscape.com/infectious/hepatitis-a is referred to as a type of viral infection that predominantly impacts the liver. This virus can be transmitted through the ingestion of [...]

FLORHAM PARK, N.J. -- Shionogi Inc., a United States subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.) will present new real-world and [...]

FOSTER CITY, Calif., Sept. 22, 2023 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced [...]

2024 FEB 18 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Fresh data on Coronavirus - COVID-19 are presented in a [...]

M2 EQUITYBITES-January 31, 2024-Microbion receives second orphan drug designation for pravibismane (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Microbion Corporation, a US-based clinical-stage pharmaceutical company, announced on Tuesday that it has received a [...]

Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp. Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market Presumed mode of action differentiated [...]

New York, USA, July 11, 2023 (GLOBE NEWSWIRE) -- Dermatophytic Onychomycosis Treatment Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), 'https://www.globenewswire.com/Tracker?data=65xfigmytSlfk7UEkwd7Rt-7zM4HNUzHkpYObU7f8Efm4XYg9RfE6B6kaTpDIrpG5N9dDnzHC-gA4Kx9Gvr3p6jfB9pWDPum8THa7oNLdm0iPUjXhKvAa5v6v8di_h9gIQ6fVkeXiTnZ4QW27dukmFhY8NoWjsphxhF5Lqtlbx72GQ9qh06qLcV3U_iZCe5GYyXhJkqlnfyN2izgEEs8tzihQFU6GQ09Uz9XBP7UJkg= Information By Product Type, [...]

M2 PRESSWIRE-June 20, 2023-: BK virus infections Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AlloVir, Amplyx Pharma, SL [...]

- Generally Safe and Well-Tolerated up to 800 mg for Seven Days with Pharmacokinetics Supportive of Once-Daily Dosing - All Doses Resulted in Strong Exposure Multiples Against Both RSV A [...]

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ('Atea'), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral [...]

On 1 Jun 2023, Pfizer Inc announced positive results from the Phase 3 programme comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam (ATM-AVI) in treating serious bacterial infections due to Gram-negative bacteria, including metallo-beta-lactamase (MBL)-producing multidrug-resistant pathogens for which there are limited or no treatment options. Data support that ATM-AVI is effective and well-tolerated, with no new safety findings and a similar safety profile to aztreonam alone. The REVISIT study compared ATM-AVI plus-minus metronidazole (MTZ) with meropenem (MER) plus-minus colistin (COL) for the treatment of complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Key results include: for patients with cIAI, cure rate in the intention to treat (ITT) analysis set was 76.4% [95% confidence interval (CI) (70.3, 81.8)] for the ATM-AVI plus-minus MTZ treatment arm vs 74.0% [95% CI (65.0, 81.7)] for the MER plus-minus COL treatment arm, with a treatment difference of 2.4% [95% CI (-12.4, 19.1)]. In the clinically evaluable (CE) analysis set, cure rate was 85.1% [95% CI (79.2, 89.9)] for ATM-AVI plus-minus MTZ versus 79.5% [95% CI (69.9, 87.1)] for MER plus-minus COL. For patients with HAP/VAP, cure rate in the ITT analysis set was 45.9% [95% CI (34.9, 57.3)] for ATM-AVI plus-minus MTZ versus 41.7% [95% CI (26.7, 57.9)] for MER plus-minus COL, with a treatment difference of 4.3% [95% CI (-25.6, 32.2)]. In the CE analysis set, cure rate was 46.7% [95% CI (32.7, 61.1)] for ATM-AVI plus-minus MTZ vs 54.5% [95% CI (34.3, 73.7)] for MER plus-minus COL. All-cause 28-day mortality rates were 4/208 (1.9%) for ATM-AVI plus-minus MTZ versus 3/104 (2.9%) for MER plus-minus COL in cIAI, and 8/74 (10.8%) for ATM-AVI plus-minus MTZ versus 7/36 (19.4%) for MER plus-minus COL in HAP/VAP. ATM-AVI plus-minus MTZ was well-tolerated, with an overall observed pattern of treatment-emergent adverse events (TEAEs) in line with that described for aztreonam alone. The incidence of serious adverse events (SAEs) was similar between treatment groups [53 (19.3%) patients in the ATM-AVI plus-minus MTZ group and 25 (18.2%) patients in the MER plus-minus COL group]. No patient treated with ATM-AVI plus-minus MTZ experienced a treatment-related SAE. These results are further supported by the ASSEMBLE study, which found that 5/12 (41.7%) of the ATM-AVI plus-minus MTZ patients with infections due to confirmed MBL-producing Gram-negative bacteria were cured at TOC versus 0/3 (0%) of those on best available therapy (BAT). ATM-AVI patients experienced TEAEs that were in line with those of aztreonam alone. No patient treated with ATM-AVI experienced a treatment-related SAE. Full results from the studies will be submitted for scientific publication. Data from the REVISIT and ASSEMBLE studies are expected to form the basis for planned regulatory filings in the European Union, United Kingdom, China, and the US in 2H 2023. Pfizer holds the global rights to commercialize ATM-AVI outside of the US and Canada, where the rights are held by its development partner AbbVie. Original source: Pfizer, website: http://www.pfizer.com/, Copyright Pfizer Inc 2023., joint venture; patents and technical know-how; research and development; antibiotics; avibactam; aztreonam; colistin; meropenem; metronidazole; AbbVie; [...]

2023 OCT 1 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Investigators publish new report on Coronavirus - COVID-19. According to [...]

MEM-ANT3310 has the potential to become the next standard of care for life-threatening infections due t o its unique coverage including carbapenem-resistant Enterobacterales and Acinetobacter baumannii Labege , France - [...]

WASHINGTON, May 4, 2023 /PRNewswire/ -- AACC has issued expert guidance on clinical testing for procalcitonin, a blood marker that helps detect serious bacterial infections and sepsis. By giving clinicians [...]

DUBLIN -- The 'Global Antibiotics Market - Distribution by Type of Drug Class, Target Disease Indication, Type of Therapy (Monotherapies and Combination Therapies), Route of Administration and Key Geographical Regions: [...]

M2 PRESSWIRE-April 27, 2023-: Global Antibiotics Market Report 2023: Need for Novel Antibiotics Targeting Multi-drug Resistant Bacterial Infections Bolsters Growth (C)1994-2023 M2 COMMUNICATIONS RDATE:27042023 The 'Global Antibiotics Market - Distribution [...]

M2 PRESSWIRE-April 12, 2023-: BK virus infections Pipeline Drugs Analysis Report, (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight (C)1994-2023 M2 COMMUNICATIONS RDATE:11042023 [...]

M2 PRESSWIRE-April 10, 2023-: BK virus infections Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight (C)1994-2023 M2 COMMUNICATIONS RDATE:06042023 (Las [...]

WATERTOWN, Mass. -- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that the U.S. Food and Drug Administration (FDA) [...]

Candida auris is a pathogenic disease commonly acquired in hospitals or long-term care facilities with no known vaccine currently available CDC has stated that 30-60% of people with C. auris [...]

New York, USA, March 15, 2023 (GLOBE NEWSWIRE) -- The Global Antifungal Drugs Market to Surpass USD 19 Billion Mark by 2027 | DelveInsight The antifungal drugs market is expanding [...]

* Phase 1 Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Supportive of Once-Daily Dosing Without Ritonavir * Preclinical Animal Data Indicate the Potential for EDP-235 to Reduce Household Transmission and [...]

Findings may provide a treatment that enables discontinuation of HIV antiretroviral therapy by preventing re-emergence of the virus Data to be presented at the Conference on Retroviruses and Opportunistic Infections [...]